Pharmaceutical

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

New J-code for iDose TR®, J7355, set to become effective July 1, 2024ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an…

6 months ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Webcasted presentation to take place at 4:40 p.m. Eastern timeDENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma,…

6 months ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

6 months ago

TOMI Environmental Solutions Receives Gold Safety Award from Highwire

FREDERICK, Md., April 03, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

6 months ago

Matinas BioPharma Prices $10 Million Registered Direct Offering

BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a…

6 months ago

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of…

6 months ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024…

6 months ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved…

6 months ago

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage…

6 months ago